LGD-4033 vs Testosterone for performance
Short answer: For performance, more users report improvement with Testosterone — 97% of 149 reports, versus 90% of 178 for LGD-4033.
LGD-4033 has 1 meta-analyses and 1 randomized trials on PubMed; Testosterone has 75 and 125.
Based on 491 reports about LGD-4033 and 822 about Testosterone. Not medical advice.
| LGD-4033 SARM | Testosterone Medication | |
|---|---|---|
| User score | 54 | 54 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 50% | 77% |
| Reports | 491 | 822 |
| Research | BResearch: Moderate | AResearch: Strong |
| Meta-analyses / RCTs | 1 / 1 | 75 / 125 |
| Mainly used for | ||
| Weight loss % reporting improvement | 94% (33) | 93% (45) |
| Appetite % reporting improvement | 60% (5) | — |
| Focus % reporting improvement | 50% (4) | 82% (28) |
| Energy % reporting improvement | 45% (22) | 92% (76) |
| Sleep % reporting improvement | 17% (6) | 79% (19) |
| Anxiety % reporting improvement | 0% (3) | 80% (25) |
| Mood % reporting improvement | 25% (24) | 88% (104) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 90% (178) | 97% (149) |
| Recovery % reporting improvement | 100% (13) | 91% (23) |
| Pain & inflammation % reporting improvement | 0% (5) | 67% (6) |
| Digestion % reporting improvement | 50% (2) | — |
| Libido % reporting improvement | 19% (27) | 93% (70) |
| Hormones % reporting improvement | 4% (48) | 90% (91) |
| Heart & lipids % reporting improvement | 0% (12) | 62% (8) |
| Skin & hair % reporting improvement | 0% (3) | 40% (5) |
| Longevity % reporting improvement | — | 50% (2) |
| Common side effects | suppression, water retention, fatigue, stomach issues | suppression, hair loss, acne, water retention |
| Typical dose reported | Not listed | 200 mg / weekly |
SARMs have a positive effect on physical performance and body composition and are associated with moderate rates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.
Clin Endocrinol (Oxf), 2025 ↗“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Menopause, 2023 ↗“Feel the best I've ever felt in my life. TRT and peptides have been game changers for me!”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate